eniporide

Eniporide is a selective inhibitor of the sodium-hydrogen exchanger isoform 1 (NHE-1), a protein that regulates intracellular pH and volume. Developed by Boehringer Ingelheim in collaboration with Merck KGaA, eniporide was primarily investigated for its potential to reduce myocardial damage during ischemia and reperfusion. The rationale for its use was that NHE-1 inhibition prevents the intracellular accumulation of sodium and the subsequent calcium overload that leads to cardiomyocyte death during the restoration of blood flow after a myocardial infarction. Although Phase 1 studies demonstrated safety and pharmacodynamic activity, the large-scale Phase 2/3 ESCAMI (Eniporide in Acute Myocardial Infarction) trial failed to show a significant reduction in infarct size or improvement in clinical outcomes in patients undergoing reperfusion therapy for acute ST-elevation myocardial infarction (STEMI). Consequently, development for this indication was terminated.

Other names

eniporide mesylateregorafenib + TAS-102-Boehringer Ingelheim-myocardial infarction-ischemia-reperfusion injury